ESMO 2019 | Trametinib: new treatment for recurrent LGSOC
Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype, accounting for about 10% of all ovarian cancers, and is characterized by alterations in the MAPK pathway and relative chemoresistance. Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses the results of the first randomized trial on LGSOC. This Phase II/III trial (NCT02101788) assess the efficacy of a MEK inhibitor trametinib compared to physician’s choice standard of care in recurrent LGSOC. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Get great new content delivered to your inboxSign up